Selected markers of bone biochemistry

Advances in Clinical Chemistry

Volumn 35, Issue , 2001, Pages 255-294

  Palicka, Vladimir ^a   Jabor, Antonin ^a   Friedecky, Bedrich ^a   Zivny, Pavel ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; HORMONE;

BONE; BONE DISEASE; BONE REMODELING; CHEMISTRY; HUMAN; METABOLISM; PHYSIOLOGY; REPRODUCIBILITY; REVIEW;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; BONE REMODELING; CYTOKINES; HORMONES; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 0034566441     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-2423(01)35018-7     Document Type: Review

References (138)

1. Akimoto S. Okumura A. Fuse H. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover in prostate cancer patients Endocr J. 45 1998 183 189
2. Antoniazzi F. Bertoldo F. Lauriola S. Sirpresi S. Gasperi E. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment J. Clin. Endocrinol. Metab. 84 1999 1992 1996
3. Banfi G. Daverio R. In vitro stability of osteocalcin Clin. Chem. 40 1994 833 834
4. Bauer D.C. Black D.M. Ott S.M. Santora A. Thompson D. Biochemical markers predict spine but not hip BMD response to alendronate: The Fracture Intervention Trial J. Bone Mineral. Res. 12 1997 S150
5. Beck-Jensen J.E. Kollerup G. Soerensen H.A. Pors Nielsen S. Soerensen O.H. A single measurement of biochemical markers of bone turnover has limited utility in the individual persons Scand. J. Clin. Lab. Invest. 57 1997 351 360
6. Blumsohn A. Eastell R. The performance and utility of biochemical markers of bone turnover: Do we know enough to use them in clinical practice? Ann. Clin. Biochem. 34 1997 449 459
7. Blumsohn A. Hannon R.A. Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays Clin. Chem. 41 1995 318 319
8. Bohic S. Pilet P. Heymann D. Effects of leukemia inhibitory factor and oncostatin M on bone mineral formed in in vitro rat bone-marrow stromal cell culture: Physicochemical aspects Biochem. Biophys. Res. Commun. 253 1998 506 513
9. Bonde M. Qvist P. Fledelius C. Riis B.J. Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated Clin. Chem. 40 1994 2022 2025
10. Bonde M. Gamero P. Fledelius C. Qvist P. Delmas P.D. Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 aminoacid sequence of the C-telopeptide of type collagen I J. Bone Miner. Res. 12 1997 1028 1034
11. Boyce B.F. Hughes D.E. Wright K.R. Xing L. Dai A. Recent advances in bone biology provide insight into pathogenesis of bone diseases Lab. Invest. 79 1999 83 94
12. Broyles D.L. Nielsen R.G. Bussett E.M. Lu W.D. Mizrahi I.A. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase Clin. Chem. 44 1998 239 247
13. Calabresi E. Lasagni I. Franceschelli F. de Leonardis V. Becorpi A. Comparison of immuno- and HPLC-assays for the measurement of urinary collagen cross-links J. Endocrinol. Invest. 17 1994 625 629
14. Calvo M.S. Eyre D.R. Grundberg C.H. Molecular basis and clinical application of biological markers of bone turnover Endocr Rev. 17 1996 333 368
15. Chae H.J. Park R.K. Chung H.T. Kang J.S. Kim M.S. Nitric oxide is a regulator of bone remodelling J. Pharm. Pharmacol. 49 1997 897 902
16. Chapurlat C.D. Delmas P.D. Bone and hormones. Effects of growth hormone on bone tissue in adults Presse Med. 28 1999 559 562
17. Cheung Ch.K. Panesar N.S. Haines Ch. Masarei J. Swaminathan R. Immunoassay of a tartrate-resistant acid phosphatase in serum Clin. Chem. 41 1995 679 685
18. Christgau S. Rosenquist Ch. Alexandersen P. Bjarnasson N.H. Ravn P. Clinical evaluation of the serum CrossLaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type 1 collagen telopeptides Clin. Chem. 44 1998 2290 2300
19. Clemens J.D. Herrich M.V. Singer F.R. Eyre D.R. Evidence that serum NTx can act as an immunochemical marker of bone resorption Clin. Chem. 43 1997 2058 2063
20. Colwell A. Russell R.G. Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption Eur. J. Clin. Invest. 23 1993 341 349
21. Damoulis P.D. Hauschka P.V. Nitric oxide acts in conjunction with proinflammatory cytokines to promote cell death in osteoblasts J. Bone Miner. Res. 12 1997 412 422
22. Deacon A.L. Hulme P. Hesp R. Green J.R. Teller M. Reeve J. Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis Clin. Chim. Acta 166 1997 297 306
23. de Castro Machado A.B. Hannon R. Eastell R. Monitoring alendronate therapy for osteoporosis J. Bone Miner. Res. 14 1999 602 608
24. Deftos L.J. Parthemore J.G. Price A.P. Changes in plasma bone GLA protein during treatment of bone disease Calcif. Tissue Int. 34 1982 121 124
25. de la Piedra C. Toural V. Rapado A. Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy Scand. J. Clin. Lab. Invest. 47 1987 587 592
26. Delmas P.D. Fraser M. Strong bones in later life: Luxury or necessity? Bull. WHO 77 1999 416 422
27. Delmas P.D. Wilson D.M. Mann K.G. Riggs B.L. Effects of renal function on plasma levels of bone Gla-protein J. Clin. Endocrinol. Metab. 57 1983 1028 1030
28. Denhardt D.T. Noda M. Osteopontin expression and function: Role in bone remodeling J. Cell. Biochem. 30–31 1998 92 102
29. de Vernejoul M.C. Dynamics of bone remodeling: Biochemical and pathophysiological basis Eur. J. Clin. Chem. Clin. Biochem. 34 1996 729 734
30. Diamond T. Campbell J. Bryant C. Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy Cancer 83 1998 1561 1566
31. Díaz Diego E.M. Guerrero R. de la Piedra C. Six osteocalcin assays compared Clin. Chem. 40 1994 2071 2077
32. Di Somma C. Colao A. Di Sarno A. Klain M. Landi M.L. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males J. Clin. Endocrinol. Metab. 83 1998 807 813
33. Drezner M.K. PHEX gene and hypophosphatemia Kidney Int. 57 2000 9 18
34. Duncan E.L. Brown M.A. Sinsheimer J. Bell J. Carr A.J. Suggestive linkage of the parathyroid receptor type I to osteoporosis J. Bone Miner. Res. 14 1999 1993 1999
35. Eriksen E.F. Brixen K. Charles P. New markers of bone metabolism: Clinical use in metabolic bone disease Eur. J. Endocrinol. 132 1995 251 256
36. Erlebacher A. Filvaroff E.H. Ye J.Q. Derynck R. Osteoblastic responses to TGF-beta during bone remodeling Mol. Biol. Cell 9 1998 1903 1918
37. Fledelius C. Johnsen A.H. Cloost P.A.C. Bonde M. Qvist P. Characterization of urinary degradation products derived from type I collagen J. Biol. Chem. 272 1997 9755 9763
38. Garnero P. Delmas P.D. Assessment of the serum alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease J. Clin. Endocrinol. Metab. 77 1993 1046 1053
39. Garnero P. Grimaux M. Seguin P. Delmas P.D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro J. Bone Miner. Res. 9 1994 255 264
40. Garnero P. Gineyts E. Arbault P. Christiansen C. Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion J. Bone Miner Res. 10 1995 641 649
41. Garnero P. Fledelius Ch. Gineyts E. Serre C.-M. Vignot E. Delmas P.D. Decreased beta-isomerisation of the C-terminal telopeptide of type I collagen alpha chain in Paget disease of bone J. Bone Miner. Res. 9 1997 1407 1415
42. Garnero P. Tsouderos Y. Maiton I. Pelissier C. Varin C. Delmas P.D. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women J. Clin. Endocrinol. Metab. 84 1999 2390 2397
43. Gerber H.P. Vu T.H. Ryan A.M. Kowalski J. Werb Z. Ferrara N. VEGF couples hypertrofic cartilage remodeling, ossification and angiogenesis during endochondral bone formation Nat. Med. 5 1999 623 628
44. Gerrits M.I. Thijssen J.H.H. Van Rijn H.M.J. Determination of pyridinoline and deoxypyridinoline in urine with special attention to retaining their stability Clin. Chem. 41 1995 571 574
45. Gertz B.J. Clemens J.D. Holland S.D. Yuan W. Greenspan S. Application of a new serum assay for type I collagen cross-linked A-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment Calcif. Tissue Int. 63 1998 102 106
46. Gomez B. Ardakani J.J. Jenkins D. Cerelli M.J. Daniloff G.Y. Kung V.T. Monoclonal antibody assay for measuring bone specific alkaline phosphatase in serum Clin. Chem. 41 1995 1560 1566
47. Gordon C.M. Grace E. Jean-Emans S. Goodman E. Crawford M.H. Leboff M.S. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa J. Bone Miner. Res. 14 1999 136 145
48. Granville D.J. Carthy C.M. Hunt D.W.C. McManus B.M. Apoptosis: Molecular aspects of cell death and disease Lab. Invest. 78 1999 893 913
49. Greenfield E.M. Bi Y. Miyauchi A. Minireview: Regulation of osteoclast activity Life Sci. 65 1999 1087 1102
50. Halleen J.M. Karp M. Viloma S. Laaksonen P. Hellman J. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies J. Bone Miner. Res. 14 1999 464 469
51. Hannon R. Blumsohn A. Naylor K. Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability J. Bone Miner. Res. 13 1998 1124 1133
52. Hanson D.A. Weis M.A.E. Bollen A.M. Maslan S.L. Singer F.R. Eyre D.R. A specific immunoassay for monitoring human bone resorption: Quantitation of type 1 collagen cross-linked A-telopeptides in urine J. Bone Miner. Res. 7 1992 1251 1258
53. Harrast S.D. Kalkwarf H.J. Effects of gestational age, maternal diabetes, and intrauterine growth retardation on markers of fetal bone turnover in amniotic fluid Calcif. Tissue Int. 62 1998 205 208
54. Heger S. Partsch C.J. Sippell W.G. Long-term outcome after depot gonadotropinreleasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function J. Clin. Endocrinol. Metab. 84 1999 4583 4590
55. Hirsch L. Watts A. McIlvain H. Rodriguez J. Romanowicz A. Efficacy of alendronate to increase BMD is similar irrespective of baseline bone turnover and age J. Bone Miner Res. 10 1995 S350
56. Hofbauer L.C. Dunstan C.R. Spelsberg T.C. Riggs B.L. Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines Biochem. Biophys. Res. Commun. 250 1998 776 784
57. Hofbauer L.C. Khosla S. Dunstan C.R. Lacey D.L. Boyle W.J. Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J. Bone Miner. Res. 15 2000 2 12
58. Hurley M.M. Tetradis S. Huang Y.F. Hock J. Kream B.E. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells J. Bone Miner. Res. 14 1999 776 783
59. Jehle P.M. Jehle D.R. Mohan S. Bohm B.O. Serum levels of insulin-like growth factor system components and relatioship to bone metabolism in type 1 and type 2 diabetes mellitus patients J. Endocrinol. 159 1998 297 306
60. Jensen C.H.H. Hansen M. Brandt J. Rasmussen B. Jensen P.B. Teisner B. Quantification of the N-terminal propeptide of human procollagen type I (PINP): Comparison of ELISA and RIA with respect to different molecular forms Clin. Chim. Acta 269 1998 31 41
61. Jimenez M.J. Balbin M. Lopez J.M. Alvarez J. Komori T. Lopez-Otin C. Collagenase 3 is a target of Cbfal, a transcription factor of the runt gene family involved in bone formation Moll. Cell Biol. 19 1999 4431 4442
62. Ju H.-S. Leung S. Brown B. Stringer M.A. Leigh S. Comparison of analytical performance and biological variability of three bone resorption assays Clin. Chem. 43 1997 1570 1576
63. Kage K. Fujita N. Oh-hara T. Ogata E. Fujita T. Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone Biochem. Biophys. Res. Commun. 254 1999 259 263
64. Kamel S. Fardellone P. Meddal B. Lorget-Gondelmann F. Sebert J.G. Brazier M. Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake Clin. Chem. 44 1998 1437 1442
65. Kanis J.A. Osteoporosis 1994 Blackwell, Scientific Oxford, UK
66. Kong Y.Y. Yoshida H. Sarosi I. Tan H.L. Timms E. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
67. Kress B.C. Mizrahi I.A. Armour W. Marcus R. Enkey R.D. Santora A.C. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women Clin. Chem. 45 1999 1009 1017
68. Kumar R. Phosphatonin—A new phosphaturetic hormone? Nephrol. Dial. Transplant. 12 1997 11 13
69. Kyd P.A. De Vooght K. Kerkhoff F. Thomas E. Faimey A. Clinical usefulness of biochemical resorption markers in osteoporosis Ann. Clin. Biochem. 36 1999 483 491
70. Langub M.C. Koszevski N.J. Turner H.V. Monier-Faguere M.C. Geng Z. MalIuche H.H. Bone resorption and mRNA expression of IL-6 receptor inpatients with renal osteodystrophy Kidney Int. 50 1996 515 520
71. Lems W.F. Van Veen G.J. Gerrits M.I. Jacobs J.W. Houben H.H. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers Br. J. Rheumatol. 37 1998 27 33
72. Lind M. Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation Acta Orthoped. Scand. 283 1998 2 37
73. Lomaga M.A. Yeh W.C. Sarosi I. Duncan G.S. Furlonger C. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling Genes Dev. 13 1999 1015 1024
74. Manolagas S.C. The role of IL-6 type cytokines and their receptors in bone Ann. N. Y. Acad. Sci. 840 1998 194 204
75. Marcus R. Recombinant human growth hormone as potential therapy for osteoporosis Baill. Clin. Endocrinol. Metab. 12 1998 251 260
76. Marcus R. Holloway L. Wells B. Turnover markers only weakly predict bone response to estrogen: The Postmenopausal Estrogen/ Progestin Interventions Trial J. Bone Miner. Res. 12 1997 S103
77. Masters P.W. Jones R.G. Purves D.A. Cooper E.H. Cooney J.M. Commercial assays for serum osteocalcin give clinically discordant results Clin. Chem. 40 1994 358 363
78. Meghji S. Henderson B. Nair S.P. Tufano M.A. Bacterial porins stimulate bone resorption Infect. Immun. 65 1997 1313 1316
79. Melton L.J. Khosla S. Atkinson E.J. O'Fallon W.M. Riggs B.L. Relationship of bone turnover to bone density and fractures J. Bone Miner. Res. 12 1997 1083 1091
80. Millet I. McCarthy T.L. Vignery A. Regulation of interleukin-6 production by prostaglandin E2 in fetal rat osteoblast: Role of protein kinase A signaling pathway J. Bone Miner. Res. 13 1998 1092 1100
81. Monier-Faugere M.C. Maltuche H.H. Role of cytokines in renal osteodystrophy Curr. Opin. Nephrol. Hypertens. 6 1997 327 332
82. Moss D.W. Diagnostic aspects of alkaline phosphatase and its isoenzymes Clin. Biochem. 20 1987 225 230
83. Nair S.P. Meghji S. Reddi K. Poole S. Miller A.D. Henderson B. Molecular chaperones stimulate bone resorption Calcif. Tissue Int. 64 1999 214 218
84. Nakasato Y.R. Janckila A.J. Halleen J.M. Vaananen H.K. Walton S.P. Yam L.T. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase Clin. Chem. 45 1999 2150 2157
85. Nakayama H. Yano T. Sagara Y. Ando K. Kasai Y. Taketani Y. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism Endocr. J. 44 1997 479 484
86. Nippoldt T.B. Nair K.S. Is there a case for DHEA replacement? Baill. Clin. Endocrinol. Metab. 12 1998 507 520
87. Okazaki H. Kurokawa T. Nakamura K. Matsushita T. Mamada K. Kawaguchi H. Stimulation of bone formation by recombinant fibroblast growth factor-2 in callotasis bone lengthening of rabbits Calcif. Tissue Int. 64 1999 542 546
88. Opdenakker G. On the roles of extracellular matrix remodeling by gelatinase B Verh. K. Acad. Geneeskd. Belg. 59 1997 489 514
89. Pacifici R. Cytokines, estrogen and postmenopausal osteoporosis—The second decade Endocrinology 139 1998 2659 2661
90. Pandian M.R. Morgan C.H. Carlton E. Serge G.V. Modified immunoradiometric assay of parathyroid hormone-related protein: Clinical application in the differential diagnosis of hypercalcemia Clin. Chem. 38 1992 282 288
91. Panigrahi K. Delmas P.D. Singer E. Ryan W. Reiss O. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum Clin. Chem. 40 1994 822 828
92. Panteghini M. Pagani F. Biological variation in bone-derived biochemical markers in serum Scand. J. Clin. Lab. Invest. 55 1995 609 616
93. Panteghini M. Pagani F. Biological variation in urinary exretion of pyridinium crosslinks: Recommendations for the optimum specimen Ann. Clin. Biochem. 33 1996 36 42
94. Papadaki H.A. Margioris A.N. Miliaki M. Steriopoulos C. Valatas W. Eliopoulos G.D. Chronic idiopathic neutropenia of adults is associated with decreased bone mineral density and alterations in bone turnover biochemical markers Eur. J. Haematol. 62 1999 3111 3116
95. Pedersen B.J. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo form procollagen and used to calibrate a radioimmunoassay of the propeptide Clin. Chem. 40 1994 811 816
96. Popp-Snijders C. Lips P. Netelenbos J.C. Intra-individual variation in bone resorption markers in urine Ann. Clin. Biochem. 33 1996 347 348
97. Price C.P. Milligan T.P. Darte C. Direct comparison of performance characteristics oftwo immunoassays for bone isoform of alkaline phosphatase in serum Clin. Chem. 43 1997 2052 2057
98. Price P.A. Parthemore J.G. Deftos L.J. New biochemical marker for bone formation: Measurement by radioimmunoassay for GLA protein in the plasma of normal subjects and patients with bone disease J. Clin. Invest. 66 1980 878 883
99. Quesada J.M. Alonso J. Gonzales J. Munoz R. Jans I. Serum beta-2 microglobulin is a marker of high bone remodelling in elderly women Mech. Ageing Dev. 102 1998 293 298
100. Raisz L.G. Physiology and pathophysiology of bone remodeling Clin. Chem. 45 1999 1353 1358
101. Raisz L.G. Prostaglandins and bone: physiology and pathophysiology Osteoarthr Cartil. 7 1999 419 421
102. Ricós C. Alvarez V. Cava F. Garefa-Lario J.V. Hernández A. Current databases on biological variation Scand. J. Clin. Lab. Invest. 59 1999 491 500
103. Robins S.P. Collagen cross-links in metabolic bone disease Acta Orthoped. Scand. 66 1995 171 175
104. Robins S.P. Duncan A. Wilson N. Evans B.J. Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation Clin. Chem. 42 1996 1621 1626
105. Robins S.P. Woitge H. Hesley R. Ju J. Seyedin S. Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption J. Bone Miner. Res. 9 1994 1643 1649
106. Rosalki S.B. Bone-origin alkaline phosphatase in plasma by wheat-germ lectin methods in bone disease Clin. Chim. Acta 226 1994 143 150
107. Rosano T.G. Peaston R.T. Bone H.G. Woitge H.W. Francis R.M. Seibel M.J. Urinary free deoxypyridinoline by chemiluminescence immunoassay: Analytical and clinical evaluation Clin. Chem. 44 1998 2126 2132
108. Rosenquist Ch. Qvist P. Bjarnason A. Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies Clin. Chem. 41 1995 1439 1445
109. Saaf M. Hilding A. Thoren M. Troell S. Hall K. Growth hormone treatment of osteoporotic postmenopausal women-A one-year placebo-controlled study Eur. J. Endocrinol. 140 1999 390 399
110. s2 Sabbieti M.G. Marchetti L. Abreu C. Montero A. Hand A.R. Prostaglandins regulate the expression of fibroblast growth factor-2 in bone Endocrinology 140 1999 434 444
111. Sato A. Iwama A. Takakura N. Nishio H. Yancopoulos G.D. Suda T. Characterization of TEK receptor tyrosine kinase and its ligands angiopoietins, in human hematopoietic progenitor cells Int. Immunol. 10 1998 1217 1222
112. Scariano J.K. Glew R.H. Bou-Serhal C.E. Clemens J.D. Garry P.J. Baumgartner R.N. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women Bone 23 1998 471 477
113. Scillitani A. Chiodini I. Carnevale V. Giannatempo G.M. Frusciante V. Skeletal involvement in female acromegalic subjects: The effects of growth hormone excess in amenorrheal and menstruating patients J. Bone Miner. Res. 12 1997 1729 1736
114. Seck T. Bretz A. Krempien R. Krempien B. Ziegler R. Pfeilschifter J. Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass Bone 24 1999 387 393
115. Seyedin S.M. Kung V.T. Daniloff Y.N. Hesley R.P. Gomez B. Immunoassay for urinary pyridinoline, the new marker of bone resorption J. Bone Miner. Res. 8 1993 635 641
116. Shaarawy M. El-Dawakhly A.S. Mosaad M. El-Sadek M.M. Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women Clin. Chem. Lab. Med. 37 1999 433 438
117. Silsand T. Reine A. Dugal S. Lunde T. Smedsrud B. Seeberg I. Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps™): Correlation to hydroxyproline Scand. J. Clin. Lab. Invest. 55 1995 187 192
118. Sokoll L.J. O'Brien M.E. Camilo M.E. Sadowski J.A. Undercarboxylated osteocalcin and development of a method to determine vitamin K status Clin. Chem. 41 1995 1121 1128
119. Spadaro J.A. Mechanical and electrical interactions in bone remodeling Bioelectromagnetics 18 1997 193 202
120. Swolin-Eide D. Ohlsson C. Effect of cortisol on the expression of interleukin-6 and interleukin-l beta in human osteoblast-like cells J. Endocrinol. 156 1998 107 114
121. Taga M. Minaguchi H. Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration Eur. J. Endocrionol. 137 1997 167 171
122. Taguchi Y. Yamamoto M. Yamate T. Lin S.C. Mocharla H. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage Proc. Assoc. Am. Physicians 110 1998 559 574
123. 2+ signaling pathway in osteoblasts Am. J. Phvsiol. 274 1998 1686 1698
124. Toogood A.A. Shalet S.M. Ageing and growth hormone status Baill. Clin. Endocrinol. Metab. 12 1998 281 296
125. Vaananen H.K. Harkonen P.L. Estrogen and bone metabolism Maturitas 23 1996 S65 S69
126. Valimaki M.J. Salmela P.I. Salmi J. Viikari J. Kataja M. Effect of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults Eur. J. Endocrinol. 140 1999 545 554
127. Van Hoof V.O. Martin M. Blockx P. Prove A. Van Oosterom A. Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum Clin. Chem. 41 1995 853 857
128. Varghese S. Yu K. Canalis E. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblast Am. J. Physiol. 276 1999 E465 E471
129. Vergnaud P. Garnero P. Meunier P.J. Breart G. Kanikagi K. Delmas P.D. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: The EPIDOS study J. Clin. Endocrinol. Metab. 82 1997 719 724
130. Walne A.J. James I.T. Perrelt D. The stability of pyridinium crosslinks in urine and serum Clin. Chim. Acta 240 1995 95 97
131. Watts N.B. Clinical utility of biochemical markers of bone remodeling Clin. Chem. 45 1999 1359 1368
132. Wichers M. Schmidt E. Bidlingmaier F. Klingmueller D. Diurnal rhythm of CrossLaps in human serum Clin. Chem. 45 1999 1858 1860
133. Withold W. Monitoring of bone turnover. Biological, preanalytical and technical criteria in the assessment of biochemical markers Eur. J. Clin. Chem. Clin. Biochem. 34 1996 785 796
134. Woitge H.W. Pecherstorfer M. Li Y. Keck A.V. Hom E. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices J. Bone Miner. Res. 14 1999 792 801
135. Yamada T. Kamiya N. Harada D. Takagi M. Effect of transforming growth factor-beta 1 on the gene expression of decorin, biglycan, and alkaline phosphatase in osteoblast precursor cells and more differentiated osteoblast cells Histochem. J. 31 1999 687 694
136. Yamaguchi T. Olozak I. Chattopadhyay N. Butters R.R. Kifor O. Expression of extracellular calcium (Ca2+0)-sensing receptor in human peripheral blood monocytes Biochem. Biophys. Res. Commun. 246 1998 501 506
137. Yasuda H. Shima N. Nakagawa N. Mochizuki S.I. Yano K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1998 1329 1337
138. Zheng S.X. Vrindts Y. Lopez M. DeGroote D. Zangerle P.F. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis Maturitas 26 1997 63 71